Secukinumab - first in class interleukin-17A inhibitor for the treatment of psoriasis
Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for rec...
Saved in:
Main Author: | Kiran Godse (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2017-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report
by: Gong J, et al.
Published: (2022) -
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
by: Vishnu Eshwar, et al.
Published: (2022) -
Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
by: Maria Concetta Fargnoli
Published: (2019) -
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience
by: Gioele Ghezzi, et al.
Published: (2024) -
Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
by: Bruna Lavinas Sayed Picciani, et al.
Published: (2021)